Navigation Links
New CE Marked Prognostic Claim for the VerifyNow P2Y12 Test
Date:5/17/2011

SAN DIEGO, May 17, 2011 /PRNewswire/ -- Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the VerifyNow P2Y12 Test is now CE marked for prognostic use in identifying patients with high residual platelet reactivity (also termed poor responders) on antiplatelet therapy (e.g. clopidogrel) who are at greater risk for future cardiovascular events.

Numerous studies have demonstrated the link between high residual platelet reactivity and greater risk of ischemic events.  Studies comprising over 3,000 patients, utilizing the VerifyNow P2Y12 Test, have shown a correlation to clinical outcomes based on PRU (P2Y12 Reaction Units) results, concluding that an on-treatment PRU of greater than or equal to 230 identifies patients at significantly greater risk for future cardiovascular events including death, heart attack and stent thrombosis.  

"Researchers, such as myself, have long been studying the relationship between platelet reactivity while on antiplatelet therapy and the risk of recurrent ischemic events in our cardiovascular patients," stated Robert F. Storey, MD, Professor of Cardiology at the University of Sheffield, England.   "The VerifyNow P2Y12 Test offers a simple and rapid means of assessing an individual's response to antiplatelet medication.  The achievement of a prognostic claim will reinforce its application to risk stratification, potentially guiding therapy in patients undergoing coronary stenting."

"The CE mark for prognostic use of the VerifyNow P2Y12 Test in risk assessment represents a major milestone for Accumetrics," said Timothy I. Still, President and CEO of Accumetrics.  "Also considering the recent inclusion of platelet reactivity testing in both the ACCF/AHA UA/NSTEMI Guidelines and the STS/SCA Blood Conservation Guidelines, the VerifyNow System is making a significant impact on how physicians are treating their cardiovascular patients."

The VerifyNow System is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.  The VerifyNow P2Y12 Test is not currently indicated for use in risk assessment in the United States. CE marking of this use is recognized in the European Economic Area.

About Accumetrics

Accumetrics is committed to enhancing quality of care for patients receiving antiplatelet therapies by providing widely accessible diagnostic tests for rapid assessment of platelet reactivity.  The VerifyNow brand is the most widely studied and recognized brand in the field of platelet reactivity.

Accumetrics' VerifyNow System helps physicians determine an individual's platelet response to multiple antiplatelet agents. Addressing every major antiplatelet drug including aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient®) and clopidogrel (Plavix®)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides valuable information to help physicians make informed treatment decisions. For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Eli Lilly and Co. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis. Effient is a registered trademark of Eli Lilly and Company.

CONTACT:  
Jakob Jakobsen
310-309-1003
jjakobsen@chandlerchiccocompanies.com

Timothy I. Still
President and CEO
Accumetrics
858-404-8260
press@accumetrics.com


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New CE Marked Test Simultaneously Detects Up To 95% of Gastrointestinal Infections in Under Five Hours
2. Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation
3. New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period
4. New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
5. 2009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name
6. Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data
7. AdvanDx Launches Fast, 90 Minutes Protocol for All CE-IVD Marked PNA FISH(R) Tests in Europe
8. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
9. FDA Moves to Stop Bogus Products Sold Over the Counter and Online that Falsely Claim to Cure and Treat STDs
10. ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®s Label Claim
11. New FDLIs Food and Drug Policy Forum Focuses on Liability Issues in Vaccine Design Defect Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
Breaking Medicine News(10 mins):